Antral Follicle Priming Before Intracytoplasmic Sperm Injection in Previously Diagnosed Low Responders: A Randomized Controlled Trial (FOLLPRIM).

Authors:
Cesar Diaz-Garcia
Cesar Diaz-Garcia
University of Gothenburg
Sweden
Mercedes Monterde
Mercedes Monterde
Instituto Universitario IVI/ INCLIVA
Spain
Jose Maria Rubio
Jose Maria Rubio
Seville University
Spain
Antonio Pellicer
Antonio Pellicer
University of Valencia
Spain

J Clin Endocrinol Metab 2015 Jul 8;100(7):2597-605. Epub 2015 May 8.

Unidad de Reproducción Humana (A.M.E., C.D.-G., J.M.R., A.P.), Área de Salud de la Mujer, Hospital Universitario y Politécnico La Fe, Universidad de Valencia, 46010 Valencia, Spain; Grupo de Investigación de Medicina Reproductiva (A.M.E., C.D.-G., M.M., J.M.R., A.P.), Instituto de Investigación Sanitario La Fe, 46026 Valencia, Spain; and Instituto Valenciano de Infertilidad (A.M.E., A.P.), Instituto Universitario IVI, 46015 Valencia, Spain.

Context: A low response to controlled ovarian hyperstimulation implies a reduced number of embryos and impaired pregnancy rate. Follicular priming with steroids before controlled ovarian hyperstimulation has been suggested to improve the subsequent ovarian response.

Objective: The purpose of this study was to determine the best follicular priming protocol in low responders and to investigate the intrafollicular mechanisms triggered by steroid hormone priming.

Design: This was a single-center, randomized, parallel, open-label, controlled trial, in two phases.

Setting: The setting was a university-based in vitro fertilization unit.

Patients: Potential low responders (n = 99) underwent a first intracytoplasmic sperm injection cycle. Confirmed low responders (n = 66) were randomized to different priming protocols before a new intracytoplasmic sperm injection.

Interventions: Randomized patients underwent one of the following priming strategies: transdermal testosterone (20 μg/kg/d), transdermal estradiol (200 μg/d), or combined estrogens and oral contraceptive pills (30 μg of ethinyl estradiol plus 150 μg of desogestrel administered during the luteal phase of two consecutive cycles) and 4 mg/d of estradiol valerate during the follicular phase between them.

Main Outcomes Measures: Metaphase II (MII) oocytes were retrieved. Gene expression levels in the granulosa cells of steroidogenesis enzymes and FSH, LH, and androgen receptors were measured.

Results: The number of retrieved MII oocytes did not differ between the interventional groups (testosterone, 2.2 ± 2.0; estrogen, 2.7 ± 1.7; and combined estrogens and oral contraceptive pills, 2.0 ± 1.3; not significant). Compared with those in nonprimed cycles, estradiol pretreatment yielded more MII oocytes (primed, 2.7 ± 1.7; nonprimed, 1.6 ± 1.2; P = .029) although the clinical pregnancy rate was higher in patients treated with testosterone (P = .003). Testosterone pretreatment increased androgen receptor expression (P = .028) compared with that for the previous cycle without priming.

Conclusions: The results of the present trial do not support the superiority of one priming strategy over the others.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2015-1194DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2015
134 Reads

Publication Analysis

Top Keywords

low responders
16
intracytoplasmic sperm
12
mii oocytes
12
controlled ovarian
8
controlled trial
8
responders randomized
8
combined estrogens
8
ovarian hyperstimulation
8
follicular priming
8
pregnancy rate
8
contraceptive pills
8
oral contraceptive
8
estrogens oral
8
sperm injection
8
priming
6
low
5
cycle confirmed
4
mg/d estradiol
4
estradiol valerate
4
cycles mg/d
4

Similar Publications